{"Abstract": [0], "The": [1, 107], "sodium\u2013glucose": [2], "cotransporter": [3], "2": [4], "inhibitor": [5], "empagliflozin": [6, 25, 76, 171, 247], "reduces": [7], "the": [8, 111, 150, 190, 215, 235, 265], "risk": [9], "of": [10, 56, 66, 110, 121, 127, 211, 219, 234, 246], "cardiovascular": [11], "death": [12, 122], "or": [13, 60, 81, 138, 142, 214, 217], "heart": [14, 21, 39, 63, 128, 135, 205, 253], "failure": [15, 40, 64, 129, 136, 206, 254], "hospitalization": [16], "in": [17, 32, 145, 149, 230, 248, 260, 264], "patients": [18, 33, 51, 168, 249], "with": [19, 52, 170, 176], "chronic": [20, 62, 204], "failure,": [22], "but": [23], "whether": [24], "also": [26], "improves": [27], "clinical": [28, 114, 173, 262], "outcomes": [29], "when": [30, 87], "initiated": [31], "who": [34], "are": [35], "hospitalized": [36, 250], "for": [37, 102, 197, 251], "acute": [38, 57, 199, 252], "is": [41, 255], "unknown.": [42], "In": [43], "this": [44], "double-blind": [45], "trial": [46, 112], "(EMPULSE;": [47], "NCT04157751": [48], "),": [49], "530": [50], "a": [53, 118, 139, 164], "primary": [54, 108, 191], "diagnosis": [55], "de": [58, 200], "novo": [59, 201], "decompensated": [61, 203], "regardless": [65, 210], "left": [67], "ventricular": [68], "ejection": [69, 212], "fraction": [70, 213], "were": [71, 84, 100, 228], "randomly": [72], "assigned": [73], "to": [74, 95, 104, 133], "receive": [75], "10": [77], "mg": [78], "once": [79], "daily": [80], "placebo.": [82], "Patients": [83], "randomized": [85], "in-hospital": [86], "clinically": [88], "stable": [89], "(median": [90], "time": [91, 132], "from": [92, 123, 147], "hospital": [93], "admission": [94], "randomization,": [96], "3": [97], "days)": [98], "and": [99, 131, 202, 207, 232, 237, 258], "treated": [101, 169], "up": [103], "90": [105, 159, 266], "days.": [106], "outcome": [109], "was": [113, 195, 208, 222], "benefit,": [115], "defined": [116], "as": [117, 161], "hierarchical": [119], "composite": [120], "any": [124], "cause,": [125], "number": [126], "events": [130, 227], "first": [134], "event,": [137], "5": [140], "point": [141], "greater": [143], "difference": [144], "change": [146], "baseline": [148], "Kansas": [151], "City": [152], "Cardiomyopathy": [153], "Questionnaire": [154], "Total": [155], "Symptom": [156], "Score": [157], "at": [158], "days,": [160], "assessed": [162], "using": [163], "win": [165, 179], "ratio.": [166], "More": [167], "had": [172], "benefit": [174, 194, 263], "compared": [175], "placebo": [177], "(stratified": [178], "ratio,": [180], "1.36;": [181], "95%": [182], "confidence": [183], "interval,": [184], "1.09\u20131.68;": [185], "P": [186], "=": [187], "0.0054),": [188], "meeting": [189], "endpoint.": [192], "Clinical": [193], "observed": [196, 209], "both": [198], "presence": [216], "absence": [218], "diabetes.": [220], "Empagliflozin": [221], "well": [223, 256], "tolerated;": [224], "serious": [225], "adverse": [226], "reported": [229], "32.3%": [231], "43.6%": [233], "empagliflozin-": [236], "placebo-treated": [238], "patients,": [239], "respectively.": [240], "These": [241], "findings": [242], "indicate": [243], "that": [244], "initiation": [245], "tolerated": [257], "results": [259], "significant": [261], "days": [267], "after": [268], "starting": [269], "treatment.": [270]}